Inflammatory Bowel Disease
Immunomodulators
Other Therapies
Disease Management Based on Clinical Severity
Epidemiology
Skyrizi outperforms Stelara in endoscopic remission at week 48 in Crohn’s disease
Although Skyrizi was noninferior to Stelara in clinical remission at week 24, it was superior in endoscopic remission at week 48 in patients with moderate to severe Crohn’s disease, according to data from the SEQUENCE trial.
Cardiovascular risk assessment recommended before use of small-molecule drugs in IBD
Although evidence suggests the risk for cardiovascular events with small-molecule drugs is low in patients with inflammatory bowel disease, experts advise screening for risk factors and stratification before initiation of therapy.
Higher adjusted AKI rate with inflammatory bowel disease vs. collagen vascular diseases
The frequency and risk of AKI in patients hospitalized with inflammatory bowel disease is higher compared with admissions with collagen vascular diseases and from the general population, a recently published study shows.
Early Diagnosis
Hormone replacement therapy improves IBD symptoms in postmenopausal women
Hormone replacement therapy was associated with improved disease symptoms, measured by the physician global assessment score, in a cohort of postmenopausal women with inflammatory bowel disease, according to data.
Higher adalimumab concentration linked to complete healing in perianal fistulizing Crohn’s
An adalimumab concentration threshold of 12.1 µg/mL “may be a target for therapeutic drug monitoring” to achieve complete fistula healing in perianal fistulizing Crohn’s disease, according to research in Clinical Gastroenterology and Hepatology.